Avexa Limited  

(Public, ASX:AVX)   Watch this stock  
Find more results for Mitchell M. Cox�
+0.0010 (20.00%)
Delayed:   10:54AM GMT+11
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range 0.01 - 0.01
52 week 0.00 - 0.02
Open 0.01
Vol / Avg. 927,111.00/816,669.00
Mkt cap 5.88M
P/E     -
Div/yield     -
EPS -0.01
Shares 980.78M
Beta     -
Inst. own     -
Nov 26, 2015
Avexa Ltd Annual Shareholders Meeting

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -1899.02% -2072.10%
Operating margin -2332.25% -2598.12%
EBITD margin - -616.93%
Return on average assets -126.71% -71.17%
Return on average equity -131.95% -74.08%
Employees 5 -
CDP Score - -


Suite 8, Level 1 61-63 Camberwell Road Hawthorn East
+61-3-88881040 (Phone)
+61-3-88881049 (Fax)

Website links


Avexa Limited is an Australia-based biotechnology company with a focus on discovery, development and commercialization of small molecules for the treatment of infectious diseases. The Company is engaged in drug development programs with establishment and support of an early access program (EAP) for apricitabine (ATC). It is also engaged in monitoring the performance of its investments, particularly the North Pratt coalmine in Alabama, the United States. The Company operates through two segments: anti-infective research and development, and investments. The Company's projects include ATC for the treatment of drug resistant human immunodeficiency virus (HIV), an HIV Integrase program and an antibiotic program for antibiotic-resistant bacterial infections. Its HIV integrase project has targeted once daily administration without a pharmacological booster, and activity against resistant mutants. It has two pre-clinical drugs: a suite of HIV-integrase inhibitors and AVX13616, an antibiotic.

Officers and directors

Jonathan Coates Interim Chief Executive Officer, Chief Scientific Officer
M. Klapakis Financial Controller
Susan W. Cox Head of Drug Development
Lee Mitchell Company Secretary
Iain M. C. Kirkwood CPA Independent Non-Executive Chairman of the Board
Age: 62
Bruce Hewett Independent Non-Executive Director
Age: 59
Allan Tan Independent Non-Executive Director
Age: 48